{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:51:42Z","timestamp":1792039902633,"version":"4.4.0"},"reference-count":29,"publisher":"Institute of Physiology of the Czech Academy of Sciences","issue":"1\/2024","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"abstract":"<jats:p>Aspirin supplemented with quercetin was reported to enhance the therapeutic effects of aspirin in a rat model of preeclampsia. In this study, the underlying mechanisms were further explored. Preeclampsia was induced by L-NAME (50 mg\/kg\/day) via oral gavage from gestation day (GD)14 to GD19. Aspirin (1.5 mg\/kg\/day) administration was performed using aspirin mixed with rodent dough from GD0 to GD19. The administration of quercetin (2 mg\/kg\/day) was performed by intraperitoneal infusion from GD0 to GD19. Protein levels were evaluated using ELISA or Western blot, and microRNA (miRNA) level was evaluated by RT-PCR. Aspirin supplemented with quercetin ameliorated the increase of systolic blood pressure (SBP), proteinuria, tumor necrosis factor-\u03b1 (TNF-\u03b1) and interleukin-6 (IL-6) levels, and improved the pregnancy outcomes in preeclampsia rats. Aspirin supplemented with quercetin inhibited miR-155 expression in preeclampsia rats. The decreased miR-155 level in placenta further increased the protein level of SOCS1 and inhibited the phosphorylation of p65. In this study, we demonstrated that aspirin supplemented with quercetin enhanced the effects of aspirin for the treatment of preeclampsia.<\/jats:p>","DOI":"10.33549\/physiolres.935196","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T13:14:57Z","timestamp":1709903697000},"page":"37-45","source":"Crossref","is-referenced-by-count":6,"title":["Protective Effects of Aspirin Supplemented With Quercetin in L-NAME-Induced Preeclampsia-Like Rats"],"prefix":"10.33549","author":[{"given":"J","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"19169","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.\tShen M, Smith GN, Rodger M, White RR, Walker MC, Wen SW. Comparison of risk factors and outcomes of gestational hypertension and pre-eclampsia. PLoS One 2017;12:e0175914. https:\/\/doi.org\/10.1371\/journal.pone.0175914","DOI":"10.1371\/journal.pone.0175914"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.\tHooijschuur MCE, Ghossein-Doha C, Kroon AA, De Leeuw PW, Zandbergen AAM, Van Kuijk SMJ, Spaanderman MEA. Metabolic syndrome and pre-eclampsia. Ultrasound Obstet Gynecol 2019;54:64-71. https:\/\/doi.org\/10.1002\/uog.20126","DOI":"10.1002\/uog.20126"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3.\tJeyabalan A. Epidemiology of preeclampsia: impact of obesity. Nutr Rev 2013;71(Suppl 1):S18-S25. https:\/\/doi.org\/10.1111\/nure.12055","DOI":"10.1111\/nure.12055"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.\tYang Y, Le Ray I, Zhu J, Zhang J, Hua J, Reilly M. Preeclampsia Prevalence, Risk Factors, and Pregnancy Outcomes in Sweden and China. JAMA Netw Open 2021;4:e218401. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.8401","DOI":"10.1001\/jamanetworkopen.2021.8401"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tRamos JGL, Sass N, Costa SHM. Preeclampsia. Rev Bras Ginecol Obstet 2017;39:496-512. https:\/\/doi.org\/10.1055\/s-0037-1604471","DOI":"10.1055\/s-0037-1604471"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.\tShen H, Zhao X, Li J, Chen Y, Liu Y, Wang Y, Liu X, Cheng W. Severe early-onset PE with or without FGR in Chinese women. Placenta 2020;101:108-114. https:\/\/doi.org\/10.1016\/j.placenta.2020.09.009","DOI":"10.1016\/j.placenta.2020.09.009"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.\tvan Esch JJA, van Heijst AF, de Haan AFJ, van der Heijden OWH. Early-onset preeclampsia is associated with perinatal mortality and severe neonatal morbidity. J Matern Fetal Neonatal Med 2017;30:2789-2794. https:\/\/doi.org\/10.1080\/14767058.2016.1263295","DOI":"10.1080\/14767058.2016.1263295"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.\tAtallah A, Lecarpentier E, Goffinet F, Doret-Dion M, Gaucherand P, Tsatsaris V. Aspirin for Prevention of Preeclampsia. Drugs 2017;77:1819-1831. https:\/\/doi.org\/10.1007\/s40265-017-0823-0","DOI":"10.1007\/s40265-017-0823-0"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.\tFontana P, Zufferey A, Daali Y, Reny JL. Antiplatelet therapy: targeting the TxA2 pathway. J Cardiovasc Transl Res 2014;7:29-38. https:\/\/doi.org\/10.1007\/s12265-013-9529-1","DOI":"10.1007\/s12265-013-9529-1"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10.\tCavalca V, Rocca B, Squellerio I, Dragani A, Veglia F, Pagliaccia F, Porro B, ET AL. In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia. Thromb Haemost 2014;112:118-127. https:\/\/doi.org\/10.1160\/TH13-10-0844","DOI":"10.1160\/th13-10-0844"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.\tSakata C, Kawasaki T, Kato Y, Abe M, Suzuki K, Ohmiya M, Funatsu T, ET AL. ASP6537, a novel highly selective cyclooxygenase-1 inhibitor, exerts potent antithrombotic effect without \"aspirin dilemma\". Thromb Res 2013;132:56-62. https:\/\/doi.org\/10.1016\/j.thromres.2013.03.005","DOI":"10.1016\/j.thromres.2013.03.005"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.\tLi Q, Yin L, Si Y, Zhang C, Meng Y, Yang W. The bioflavonoid quercetin improves pathophysiology in a rat model of preeclampsia. Biomed Pharmacother 2020;127:110122. https:\/\/doi.org\/10.1016\/j.biopha.2020.110122","DOI":"10.1016\/j.biopha.2020.110122"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.\tYang S, Song L, Shi X, Zhao N, Ma Y. Ameliorative effects of pre-eclampsia by quercetin supplement to aspirin in a rat model induced by L-NAME. Biomed Pharmacother 2019;116:108969. https:\/\/doi.org\/10.1016\/j.biopha.2019.108969","DOI":"10.1016\/j.biopha.2019.108969"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.\tBokslag A, van Weissenbruch M, Mol BW, de Groot CJ. Preeclampsia; short and long-term consequences for mother and neonate. Early Hum Dev 2016;102:47-50. https:\/\/doi.org\/10.1016\/j.earlhumdev.2016.09.007","DOI":"10.1016\/j.earlhumdev.2016.09.007"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.\tRana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: Pathophysiology, Challenges, and Perspectives. Circ Res 2019;124:1094-1112. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.313276","DOI":"10.1161\/circresaha.118.313276"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16.\tShamshirsaz AA, Paidas M, Krikun G. Preeclampsia, hypoxia, thrombosis, and inflammation. J Pregnancy 2012;2012:374047. https:\/\/doi.org\/10.1155\/2012\/374047","DOI":"10.1155\/2012\/374047"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17.\tKnight M, Duley L, Henderson-Smart DJ, King JF. Antiplatelet agents for preventing and treating pre-eclampsia. Cochrane Database Syst Rev 2000;(2):CD000492. https:\/\/doi.org\/10.1002\/14651858.CD000492","DOI":"10.1002\/14651858.cd000492"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.\tCoomarasamy A, Honest H, Papaioannou S, Gee H, Khan KS. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol 2003;101:1319-1332. https:\/\/doi.org\/10.1097\/00006250-200306000-00030","DOI":"10.1097\/00006250-200306000-00030"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19.\tDuley L, Meher S, Hunter KE, Seidler AL, Askie LM. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2019;2019:CD004659. https:\/\/doi.org\/10.1002\/14651858.CD004659.pub3","DOI":"10.1002\/14651858.cd004659.pub3"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20.\tUstUn Y, Engin-UstUn Y, Ozkaplan E, Otlu B, Sait TekerekoGlu M. Association of Helicobacter pylori infection with systemic inflammation in preeclampsia. J Matern Fetal Neonatal Med 2010;23:311-314. https:\/\/doi.org\/10.3109\/14767050903121456","DOI":"10.1080\/14767050903121456"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21.\tSzarka A, Rigo J Jr, Lazar L, Beko G, Molvarec A. Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol 2010;11:59. https:\/\/doi.org\/10.1186\/1471-2172-11-59","DOI":"10.1186\/1471-2172-11-59"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22.\tBors W, Michel C, Saran M. Flavonoid antioxidants: rate constants for reactions with oxygen radicals. Methods Enzymol 1994;234:420-429. https:\/\/doi.org\/10.1016\/0076-6879(94)34112-5","DOI":"10.1016\/0076-6879(94)34112-5"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23.\tKleemann R, Verschuren L, Morrison M, Zadelaar S, van Erk MJ, Wielinga PY, Kooistra T. Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis 2011;218:44-52. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.04.023","DOI":"10.1016\/j.atherosclerosis.2011.04.023"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24.\tMorales-Prieto DM, Ospina-Prieto S, Chaiwangyen W, Schoenleben M, Markert UR. Pregnancy-associated miRNA-clusters. J Reprod Immunol 2013;97:51-61. https:\/\/doi.org\/10.1016\/j.jri.2012.11.001","DOI":"10.1016\/j.jri.2012.11.001"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25.\tKarin-Kujundzic V, Sola IM, Predavec N, Potkonjak A, Somen E, Mioc P, Serman A, ET AL. Novel Epigenetic Biomarkers in Pregnancy-Related Disorders and Cancers. Cells 2019;8:1459 https:\/\/doi.org\/10.3390\/cells8111459","DOI":"10.3390\/cells8111459"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26.\tLv Y, Lu C, Ji X, Miao Z, Long W, Ding H, Lv M. Roles of microRNAs in preeclampsia. J Cell Physiol 2019;234:1052-1061. https:\/\/doi.org\/10.1002\/jcp.27291","DOI":"10.1002\/jcp.27291"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27.\tPineles BL, Romero R, Montenegro D, Tarca AL, Han YM, Kim YM, Draghici S, ET AL. Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol 2007;196:261e1-e6. https:\/\/doi.org\/10.1016\/j.ajog.2007.01.008","DOI":"10.1016\/j.ajog.2007.01.008"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28.\tZhang Y, Diao Z, Su L, Sun H, Li R, Cui H, Hu Y. MicroRNA-155 contributes to preeclampsia by down-regulating CYR61. Am J Obstet Gynecol 2010;202:466e1-e7. https:\/\/doi.org\/10.1016\/j.ajog.2010.01.057","DOI":"10.1016\/j.ajog.2010.01.057"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29.\tJiang K, Yang J, Guo S, Zhao G, Wu H, Deng G. Peripheral Circulating Exosome-Mediated Delivery of miR-155 as a Novel Mechanism for Acute Lung Inflammation. Mol Ther 2019;27:1758-1771. https:\/\/doi.org\/10.1016\/j.ymthe.2019.07.003","DOI":"10.1016\/j.ymthe.2019.07.003"}],"container-title":["Physiological Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T13:15:06Z","timestamp":1709903706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biomed.cas.cz\/physiolres\/pdf\/2024\/73_37.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":29,"journal-issue":{"issue":"1\/2024","published-online":{"date-parts":[[2024,3,6]]}},"URL":"https:\/\/doi.org\/10.33549\/physiolres.935196","relation":{},"ISSN":["1802-9973","0862-8408"],"issn-type":[{"value":"1802-9973","type":"electronic"},{"value":"0862-8408","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,6]]}}}